Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunmax Biotechnology Co's revenue for the
three
months ended in Mar. 2026 was NT$565 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was NT$2,037 Mil.
Sunmax Biotechnology Co's Revenue per Share for the
three
months ended in Mar. 2026 was NT$10.36.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$37.34.
Warning Sign:
Sunmax Biotechnology Co Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Sunmax Biotechnology Co was 4.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 13.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 19.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 36.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Sunmax Biotechnology Co's highest 3-Year average Revenue per Share Growth Rate was 64.60% per year. The lowest was -9.80% per year. And the median was 22.90% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sunmax Biotechnology Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunmax Biotechnology Co Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunmax Biotechnology Co's Revenue distribution charts can be found below:
* The bar in red indicates where Sunmax Biotechnology Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2,037 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunmax Biotechnology Co (ROCO:4728) has a Revenue of NT$2,037 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Sunmax Biotechnology Co and its competitors.
Is Sunmax Biotechnology Co's Revenue too high?
Sunmax Biotechnology Co's current Revenue is NT$2,037 Mil. Overall, Sunmax Biotechnology Co has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sunmax Biotechnology Co's Revenue compare to VRTX and REGN?
Sunmax Biotechnology Co's Revenue of NT$2,037 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Sunmax Biotechnology Co and its competitors. Sunmax Biotechnology Co's current Revenue is NT$2,037 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunmax Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Sunmax Biotechnology Co (ROCO:4728) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$345.62, compared to a current price of NT$385.50 — trading 11.5% above its estimated fair value. The current Revenue is NT$2,037 Mil. Sunmax Biotechnology Co's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Sunmax Biotechnology Co (ROCO:4728), the current Revenue is NT$2,037 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunmax Biotechnology Co (ROCO:4728) Overvalued in 2026?
Based on GuruFocus' analysis, Sunmax Biotechnology Co stock appears to be overvalued.
The current stock price of NT$385.50 is trading 11.5% above its estimated GF Value™ of NT$345.62.
GuruFocus considers Sunmax Biotechnology Co to be Modestly Overvalued.
Key valuation signals for ROCO:4728:
Revenue: NT$2,037 Mil
GF Value™: NT$345.62 vs. price of NT$385.50 (11.5% above fair value)
No single metric tells the full story. See the ROCO:4728 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.
88GF Score
Get the complete analysis for ROCO:4728
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4728 has been successfully added to your 
